Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Chiglitazar in Hepatic Impairment
NCT05515445Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Dec 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of chiglitazar in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Akeso, Inc. Primary endpoints: Maximum Plasma Concentration at 4 days, Area Under the Curve from time 0 to last measurable concentration at 4 days and 1 more. Started Dec 2022; status: completed.
02
Drugs
chiglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05515445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515445.